Pfizer’s drug for advanced lung cancer shows promising long-term trial results

CNBC May 31, 2024
Annika Kim Constantino

Key Points

– Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the condition.

– Lorbrena is already approved in the U.S. for treating adults with advanced non-small cell lung cancer who have a mutation in a gene called ALK.

– Pfizer will present the results on Friday at the American Society of Clinical Oncology’s annual meeting in Chicago.

CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition.

The company’s...

Today's Sponsors

Today's Sponsor